vorasidenib
servier
['vorasidenib', 'indigo']
late breaking at #asco23: mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. the idh inhibitor vorasidenib improved progression-free survival as compared with placebo. full results of the indigo trial: 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.